Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough
Tài liệu tham khảo
Ramalingam, 2020, Overall survival with osimertinib in untreated, EGFR-Mutated advanced NSCLC, N. Engl. J. Med., 382, 41, 10.1056/NEJMoa1913662
Zhou, 2019, Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study, Lancet Respir. Med., 7, 437, 10.1016/S2213-2600(19)30053-0
Shen, 2020, First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer, Cancer Med., 9, 3310, 10.1002/cam4.2972
Subbiah, 2020, Pan-cancer efficacy of vemurafenib in BRAF (V600)-mutant non-melanoma cancers, Cancer Discov., 10, 657, 10.1158/2159-8290.CD-19-1265
Borghaei, 2019, 24-month overall survival from KEYNOTE-021 cohort g: pemetrexed and carboplatin with or without Pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer, J. Thorac. Oncol., 14, 124, 10.1016/j.jtho.2018.08.004
El-Deiry, 2019, The current state of molecular testing in the treatment of patients with solid tumors, 2019, CA Cancer J. Clin., 69, 305, 10.3322/caac.21560
Manie, 2001, The RET receptor: function in development and dysfunction in congenital malformation, Trends Genet.: TIG, 17, 580, 10.1016/S0168-9525(01)02420-9
Coulpier, 2002, Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival, J. Biol. Chem., 277, 1991, 10.1074/jbc.M107992200
Jain, 2006, Critical and distinct roles for key RET tyrosine docking sites in renal development, Genes Dev., 20, 321, 10.1101/gad.1387206
Jijiwa, 2008, GDNF-mediated signaling via RET tyrosine 1062 is essential for maintenance of spermatogonial stem cells, Genes Cells, 13, 365, 10.1111/j.1365-2443.2008.01171.x
Takahashi, 1985, Activation of a novel human transforming gene, ret, by DNA rearrangement, Cell, 42, 581, 10.1016/0092-8674(85)90115-1
Romei, 2016, A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma, Nat. Rev. Endocrinol., 12, 192, 10.1038/nrendo.2016.11
Kato, 2017, RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients, Clin. Cancer Res., 23, 1988, 10.1158/1078-0432.CCR-16-1679
Matsubara, 2012, Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad, J. Thorac. Oncol., 7, 1872, 10.1097/JTO.0b013e3182721ed1
Nikiforov, 2011, Molecular genetics and diagnosis of thyroid cancer, Nat. Rev. Endocrinol., 7, 569, 10.1038/nrendo.2011.142
Wang, 2012, RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer, J. Clin. Oncol., 30, 4352, 10.1200/JCO.2012.44.1477
Lee, 2019, Tracing oncogene rearrangements in the mutational history of lung adenocarcinoma, Cell, 177, 10.1016/j.cell.2019.05.013
Rich, 2019, Analysis of cell-free DNA from 32,989 advanced cancers reveals novel Co-occurring activating RET alterations and oncogenic signaling pathway aberrations, Clin. Cancer Res., 25, 5832, 10.1158/1078-0432.CCR-18-4049
Schrock, 2018, Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors, J. Thorac. Oncol., 13, 1312, 10.1016/j.jtho.2018.05.027
Klempner, 2015, Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI, Lung Cancer, 89, 357, 10.1016/j.lungcan.2015.06.021
Hida, 2019, A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma, Lung Cancer, 138, 124, 10.1016/j.lungcan.2019.09.011
Horiike, 2016, Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer, Lung Cancer, 93, 43, 10.1016/j.lungcan.2015.12.011
Sherman, 2016, Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer, Cancer, 122, 3856, 10.1002/cncr.30252
Drilon, 2016, Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial, Lancet Oncol., 17, 1653, 10.1016/S1470-2045(16)30562-9
Uchino, 2017, Safety and tolerability of vandetanib in japanese patients with medullary thyroid cancer: a phase I/Ii open-label study, Endocr. Pract., 23, 149, 10.4158/EP161259.OR
Yoh, 2017, Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial, Lancet Respir. Med., 5, 42, 10.1016/S2213-2600(16)30322-8
Lee, 2017, Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial, Ann. Oncol., 28, 292, 10.1093/annonc/mdw559
Andreev-Drakhlin, 2019, The landscape of RET alterations from 56,970 adult patients with cancer: clinical implications, J. Clin. Oncol., 37
Kreuter, 2013, Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study, Ann. Oncol., 24, 986, 10.1093/annonc/mds578
Smallridge, 2012, American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer, Thyroid, 22, 1104, 10.1089/thy.2012.0302
Drilon, 2016, Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers, Ann. Oncol., 27, 1286, 10.1093/annonc/mdw163
Subbiah, 2018, Selective RET kinase inhibition for patients with RET-altered cancers, Ann. Oncol., 29, 1869, 10.1093/annonc/mdy137
Subbiah, 2018, Precision targeted therapy with BLU-667 for RET-driven cancers, Cancer Discov., 8, 836, 10.1158/2159-8290.CD-18-0338
Wirth, 2020, Efficacy of selpercatinib in RET-altered thyroid cancers, N. Engl. J. Med., 383, 825, 10.1056/NEJMoa2005651
Drilon, 2020, Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer, N. Engl. J. Med., 383, 813, 10.1056/NEJMoa2005653
Ishizaka, 1989, Human ret proto-oncogene mapped to chromosome 10q11.2, Oncogene, 4, 1519
Alberti, 2003, RET and NTRK1 proto-oncogenes in human diseases, J. Cell. Physiol., 195, 168, 10.1002/jcp.10252
Phay, 2010, Targeting RET receptor tyrosine kinase activation in cancer, Clin. Cancer Res., 16, 5936, 10.1158/1078-0432.CCR-09-0786
Fagerberg, 2014, Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics, Mol. Cell. Proteomics: MCP, 13, 397, 10.1074/mcp.M113.035600
Ito, 2005, Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers, Surgery, 138, 788, 10.1016/j.surg.2005.07.007
Zeng, 2008, The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer, J. Int. Med. Res., 36, 654, 10.1177/147323000803600406
Morandi, 2013, GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors, Cancer Res., 73, 3783, 10.1158/0008-5472.CAN-12-4265
Gattelli, 2013, Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells, EMBO Mol. Med., 5, 1335, 10.1002/emmm.201302625
Amit, 2017, Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma, Oncogene, 36, 3232, 10.1038/onc.2016.483
Dawson, 1998, Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer, J. Natl. Cancer Inst., 90, 519, 10.1093/jnci/90.7.519
Ban, 2017, RET signaling in prostate cancer, Clin. Cancer Res., 23, 4885, 10.1158/1078-0432.CCR-17-0528
Wang, 2016, Prognostic and predictive values of subcellular localisation of RET in renal clear-cell carcinoma, Dis. Markers, 2016, 10.1155/2016/6870470
Flavin, 2012, RET protein expression in papillary renal cell carcinoma, Urol. Oncol., 30, 900, 10.1016/j.urolonc.2010.08.025
Spanheimer, 2014, Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer, Clin. Cancer Res., 20, 2115, 10.1158/1078-0432.CCR-13-2221
Plaza-Menacho, 2010, Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance, Oncogene, 29, 4648, 10.1038/onc.2010.209
Arighi, 2005, RET tyrosine kinase signaling in development and cancer, Cytokine Growth Factor Rev., 16, 441, 10.1016/j.cytogfr.2005.05.010
Mulligan, 2014, RET revisited: expanding the oncogenic portfolio, Nat. Rev. Cancer, 14, 173, 10.1038/nrc3680
Mulligan, 1993, Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A, Nature, 363, 458, 10.1038/363458a0
Romei, 2012, Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer, Thyroid, 22, 476, 10.1089/thy.2011.0358
Romei, 2016, New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations, J. Med. Genet., 53, 729, 10.1136/jmedgenet-2016-103833
Maciel, 2019, Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study, Endocr. Connect., 8, 289, 10.1530/EC-18-0506
Sarika, 2012, High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece, Clin. Endocrinol. (Oxf), 77, 857, 10.1111/j.1365-2265.2012.04462.x
Fanis, 2018, Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect, J. Endocrinol. Invest., 41, 1149, 10.1007/s40618-018-0841-0
Berndt, 1998, A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A, J. Clin. Endocrinol. Metab., 83, 770
Qian, 2014, KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer, Mol. Cancer, 13
Ju, 2012, A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing, Genome Res., 22, 436, 10.1101/gr.133645.111
Huang, 2016, Preclinical modeling of KIF5B-RET fusion lung adenocarcinoma, Mol. Cancer Ther., 15, 2521, 10.1158/1535-7163.MCT-16-0258
Tsai, 2015, Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion, Lung Cancer, 88, 208, 10.1016/j.lungcan.2015.02.018
Pietrantonio, 2018, RET fusions in a small subset of advanced colorectal cancers at risk of being neglected, Ann. Oncol., 29, 1394, 10.1093/annonc/mdy090
Wang, 2019, Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations, Cancer Med.
Yao, 2019, RET fusion in first/third-generation EGFR-TKIs resistance in advanced non-small cell lung cancer, J. Clin. Oncol., 37
Piotrowska, 2018, Landscape of acquired resistance to osimertinib in EGFR-Mutant NSCLC and clinical validation of combined EGFR and RET inhibition with Osimertinib and BLU-667 for acquired RET fusion, Cancer Discov., 8, 1529, 10.1158/2159-8290.CD-18-1022
Xu, 2019, Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors, Cancer Manag. Res., 11, 6343, 10.2147/CMAR.S197337
Berghoff, 2019, Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC)_ summary of a multidisciplinary roundtable discussion, ESMO Open, 4, 10.1136/esmoopen-2019-000498
Mazieres, 2019, Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann. Oncol., 30, 1321, 10.1093/annonc/mdz167
Song, 2016, Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma, J. Transl. Med., 14, 188, 10.1186/s12967-016-0943-4
Offin, 2019, Immunophenotype and response to immunotherapy of RET-rearranged lung cancers, JCO Precis. Oncol., 3
Sarfaty, 2017, RET fusion lung carcinoma: response to therapy and clinical features in a case series of 14 patients, Clin. Lung Cancer, 18, 10.1016/j.cllc.2016.09.003
Ceolin, 2019, Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives, Endocr. Relat. Cancer, 26, R499, 10.1530/ERC-18-0574
Capozzi, 2019, Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment, Cancer Manag. Res., 11, 3847, 10.2147/CMAR.S188316
Starenki, 2017, Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells, Cancer Biol. Ther., 18, 473, 10.1080/15384047.2017.1323594
Manz, 2019, Efficacy and safety of approved first-line tyrosine kinase inhibitor treatments in metastatic renal cell carcinoma: a network meta-analysis, Adv. Ther.
Ravaud, 2017, A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study, Eur. J. Cancer, 76, 110, 10.1016/j.ejca.2017.01.029
Wedge, 2002, ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration, Cancer Res., 62, 4645
Okamoto, 2013, Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models, Cancer Lett., 340, 97, 10.1016/j.canlet.2013.07.007
Mross, 2012, A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors, Clin. Cancer Res., 18, 2658, 10.1158/1078-0432.CCR-11-1900
Bentzien, 2013, In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer, Thyroid, 23, 1569, 10.1089/thy.2013.0137
Plenker, 2017, Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors, Sci. Transl. Med., 9, 10.1126/scitranslmed.aah6144
Roskoski, 2016, Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes, Pharmacol. Res., 103, 26, 10.1016/j.phrs.2015.10.021
Plaza-Menacho, 2014, Mechanisms of RET signaling in cancer: current and future implications for targeted therapy, Cell. Signal., 26, 1743, 10.1016/j.cellsig.2014.03.032
Saito, 2014, A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis, Carcinogenesis, 35, 2452, 10.1093/carcin/bgu158
Lipson, 2012, Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies, Nat. Med., 18, 382, 10.1038/nm.2673
Yakes, 2011, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth, Mol. Cancer Ther., 10, 2298, 10.1158/1535-7163.MCT-11-0264
Yoh, 2018, LURET: final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer, Ann. Oncol., 29, 10.1093/annonc/mdy292.108
Gautschi, 2017, Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry, J. Clin. Oncol., 35, 1403, 10.1200/JCO.2016.70.9352
Platt, 2015, A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies, BMC Cancer, 15
Wells, 2012, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial, J. Clin. Oncol., 30, 134, 10.1200/JCO.2011.35.5040
Fox, 2013, Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma, Clin. Cancer Res., 19, 4239, 10.1158/1078-0432.CCR-13-0071
Wang, 2019, Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase III study, Zhonghua er bi yan hou tou jing wai ke za zhi = Chin. J. Otorhinolaryngol. Head Neck Surg., 54, 439
Elisei, 2013, Cabozantinib in progressive medullary thyroid cancer, J. Clin. Oncol., 31, 3639, 10.1200/JCO.2012.48.4659
Schlumberger, 2016, A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer, Clin. Cancer Res., 22, 44, 10.1158/1078-0432.CCR-15-1127
Brose, 2017, Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial, J. Clin. Oncol., 35, 2692, 10.1200/JCO.2016.71.6472
Carr, 2010, Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation, Clin. Cancer Res., 16, 5260, 10.1158/1078-0432.CCR-10-0994
Lim, 2015, An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer, Eur. J. Cancer, 51, 1588, 10.1016/j.ejca.2015.05.020
Schlumberger, 2009, Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer, J. Clin. Oncol., 27, 3794, 10.1200/JCO.2008.18.7815
Castellanos, 2017, Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer, J. Thorac. Oncol., 12, 612, 10.1016/j.jtho.2016.12.014
Caccese, 2016, Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice, Expert Opin. Pharmacother., 17, 2253, 10.1080/14656566.2016.1242578
Zhang, 2015, Targeting brain metastases in ALK-rearranged non-small-cell lung cancer, Lancet Oncol., 16, 10.1016/S1470-2045(15)00013-3
Rangachari, 2015, Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers, Lung Cancer, 88, 108, 10.1016/j.lungcan.2015.01.020
Kalkanis, 2010, The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline, J. Neurooncol., 96, 33, 10.1007/s11060-009-0061-8
Linskey, 2010, The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline, J. Neurooncol., 96, 45, 10.1007/s11060-009-0073-4
Drilon, 2017, Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers, J. Clin. Oncol., 35, 10.1200/JCO.2017.35.15_suppl.9069
Eichler, 2010, EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer, Neurooncology, 12, 1193
Singh, 2019, Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: a systematic review and meta-analysis of multidisciplinary approaches, Radiother. Oncol., 144, 165, 10.1016/j.radonc.2019.11.010
Arai, 2017, In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET, Oncotarget, 8, 73766, 10.18632/oncotarget.17900
Lin, 2016, Clinical activity of alectinib in advanced RET-Rearranged non-small cell lung Cancer, J. Thorac. Oncol., 11, 2027, 10.1016/j.jtho.2016.08.126
Takeuchi, 2017, Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol, J. Med. Invest.: JMI, 64, 317, 10.2152/jmi.64.317
Velcheti, 2017, Intracranial and systemic response to alectinib in a patient with RET-KIF5B oncogenic fusion, J. Thorac. Oncol., 12, e98, 10.1016/j.jtho.2017.03.007
Takeuchi, 2016, Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study), Ann. Oncol., 27, 185, 10.1093/annonc/mdv501
Camidge, 2019, Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-Positive advanced non-small cell lung cancer in the global phase III ALEX study, J. Thorac. Oncol., 14, 1233, 10.1016/j.jtho.2019.03.007
Yanagitani, 2019, Alectinib in previously treated RET-rearranged advanced non-small-cell lung cancer: a phase 1/2 trial (ALL-RET), J. Thorac. Oncol., 14, 10.1016/j.jtho.2019.08.411
Kodama, 2014, Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance, Cancer Lett., 351, 215, 10.1016/j.canlet.2014.05.020
Gadgeel, 2014, Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study, Lancet Oncol., 15, 1119, 10.1016/S1470-2045(14)70362-6
Ou, 2016, Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study, J. Clin. Oncol., 34, 661, 10.1200/JCO.2015.63.9443
Shaw, 2016, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, Lancet Oncol., 17, 234, 10.1016/S1470-2045(15)00488-X
Gadgeel, 2016, Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer, J. Clin. Oncol., 34, 4079, 10.1200/JCO.2016.68.4639
Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, N. Engl. J. Med., 377, 829, 10.1056/NEJMoa1704795
Vivek Subbiah, 2020, 9516
Drilon, 2019, Registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers, J. Thorac. Oncol., 14, S6, 10.1016/j.jtho.2019.08.059
Taylor, 2019, Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers, J. Clin. Oncol., 37
Gainor, 2020, 9515
Drilon, 2017, 210 A phase 1b study of RXDX‑105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC, Ann. Oncol., 28
Gainor, 2019, Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion plus non-small cell lung cancer (NSCLC), J. Clin. Oncol., 37
2018, LOXO-292 reins in RET-driven tumors, Cancer Discov., 8, 904, 10.1158/2159-8290.CD-NB2018-070
Guo, 2019, Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases, Jco Precis. Oncol., 3
Oxnard, 2018, OA12.07 clinical activity of LOXO-292, a highly selective RET inhibitor, in patients with RET fusion+ non-small cell lung cancer, J. Thorac. Oncol., 13, 10.1016/j.jtho.2018.08.304